Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence
Objectives To compare the premarket and postmarket evidence of safety and efficacy of direct oral anticoagulants approved for stroke prevention in atrial fibrillation patients across four major regulatory agencies.Design Cross-sectional.Setting European Medicines Association (EMA), US Food and Drug...
Saved in:
| Main Authors: | Joseph S Ross, Tianna Zhou, Maryam Mooghali |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-10-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/10/e090376.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DIRECT ORAL ANTICOAGULANTS
by: I. Tzoran, et al.
Published: (2016-06-01) -
Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
by: Raghavendra Charan P Makam, et al.
Published: (2018-01-01) -
Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011–2023: a cross-sectional analysis
by: Steven Joffe, et al.
Published: (2025-05-01) -
Direct oral anticoagulants for electrical cardioversion
by: A. N. Volovchenko, et al.
Published: (2021-07-01) -
Direct Oral Anticoagulants in Cancer Patients
by: Nicolas Bonadies, et al.
Published: (2024-10-01)